PDCD1 and neoplasm: Interestingly, a different version of fresolimumab, which contains a single mutation in the Fc region (SAR439459), has been shown not only to suppress the negative effects of TGF-β on NK and T cells, but also to enhance the anti-tumor response of anti-PD-1 therapy [122,133].